scholarly journals Bisphosphonates and breast cancer survival: a meta-analysis and trial sequential analysis of 81508 participants from 23 prospective epidemiological studies

Aging ◽  
2021 ◽  
Vol 13 (15) ◽  
pp. 19835-19866
Author(s):  
YuPeng Liu ◽  
Shu Zhao ◽  
YuXue Zhang ◽  
Justina Ucheojor Onwuka ◽  
QingYuan Zhang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Sequential Analysis ◽  
Cancer Survival ◽  
Meta Analysis ◽  
Epidemiological Studies ◽  
Breast Cancer Survival ◽  
Trial Sequential Analysis

Relationship of Socio Economic Status, Income, and Education with the Survival Rate of Breast Cancer: A Meta-Analysis

2020 ◽  
Author(s):  
Majid TAHERI ◽  
Mohammad TAVAKOL ◽  
Mohammad Esmaeil AKBARI ◽  
Amir ALMASI-HASHIANI ◽  
Mahmoud ABBASI
Keyword(s):  
Breast Cancer ◽  
Cancer Survival ◽  
Economic Status ◽  
Meta Analysis ◽  
Epidemiological Studies ◽  
Social Determinant ◽  
Breast Cancer Survival ◽  
Socio Economic Status ◽  
Academic Level ◽  
High Level

Background: Despite our awareness of the significant effect of Social Determinant of Health (SDoH) such as Socio Economic Status (SES), income and education on breast cancer survival, there was a serious lack of information about the effect of different level of these factors on breast cancer survival. So far, no meta-analysis has been conducted with this aim, but this gap was addressed by this meta-analysis. Methods: Main electronic databases such as PubMed, Web of Science, and Scopus were investigated up to January 2019. Epidemiological studies focusing on the association between SDoH and breast cancer were singled out. Q-test and I2 statistic were used to study the heterogeneity across studies. Begg's and Egger's tests were applied to explore the likelihood of the publication bias. The results were reported as hazard ratio (HR) with 95% confidence intervals (CI) through a random-effects model. Results: We identified 7,653 references and included 25 studies involving 1,497,881 participants. The HR estimate of breast cancer survival was 0.82 (0.67, 0.98) among high level of SES, 0.82 (0.70, 0.94) among high level of income and 0.72 (0.66, 0.78) among academic level of education. Conclusion: The SES, income, and education were associated with breast cancer survival, although the association was not very strong. However, there was a significant association between the levels of these factors and breast cancer survival.

scholarly journals Clinical Effectiveness and Safety of Chinese Herbal Medicine Compound Kushen Injection as an Add-On Treatment for Breast Cancer: A Systematic Review and Meta-Analysis

2022 ◽  
Vol 2022 ◽  
pp. 1-16
Author(s):  
Bao-Yong Lai ◽  
Ai-Jing Chu ◽  
Bo-Wen Yu ◽  
Li-Yan Jia ◽  
Ying-Yi Fan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Sequential Analysis ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Objective Response ◽  
Trial Sequential Analysis ◽  
Karnofsky Performance Scale ◽  
Improvement Rate ◽  
Score Improvement ◽  
Compound Kushen Injection

Objective. To systematically evaluate the effect and safety of compound Kushen injection (CKI) as an add-on treatment on the treatment for breast cancer. Methods. We searched eight major electronic databases from their inception to November 1, 2021, for randomized clinical trials (RCTs) comparing CKI plus chemotherapy with chemotherapy alone. Primary outcomes included objective response rate (ORR) and disease control rate (DCR), health-related quality of life (HRQoL), progression-free survival (PFS), and overall survival (OS). Secondary outcomes included adverse drug reactions (ADRs) and tumor marker level. We used Cochrane’s RevMan 5.3 for data analysis. The GRADEpro was used to appraise the certainty of evidence. Trial sequential analysis (TSA) was applied to estimate the required sample size in a meta-analysis and test the robustness of the current results. Results. Thirty RCTs with 2556 participants were totally included. CKI plus chemotherapy showed significant effects in increasing ORR (RR 1.30, 95%CI [1.18, 1.43], I2 = 27%, n = 1694), increasing DCR (RR 1.21, 95%CI [1.15, 1.28], I2 = 16%, n = 1627), increasing HRQol as measured by Karnofsky Performance Scale (KPS) score improvement rate (RR 1.42, 95% CI [1.26, 1.61], I2 = 37%, n = 1172), increasing the PFS (MD 2.24 months, 95%CI [1.26, 3.22], n = 94) and the OS (MD 2.24 months, 95%CI [1.45, 3.43], n = 94), compared to chemotherapy alone. The results showed that CKI plus chemotherapy had a lower risk of ADRs than that of chemotherapy alone group. The certainty of evidence of the included trials was generally low to very low. TSA for ORR and KPS score improvement rate demonstrated that the current results reached a sufficient power regarding both numbers of trials and participants. Conclusions. Low certainty of evidence suggested that the combination of CKI and conventional chemotherapy appeared to improve ORR, DCR, and KPS score in breast cancer patients. Conclusions about PFS and OS could not be drawn due to lack of evidence. Additionally, CKI appeared to relieve the risk of ADRs in patients with breast cancer receiving chemotherapies. However, due to weak evidence, the findings should be further confirmed in large and rigorous trials.

scholarly journals Post-diagnosis Soy Food Intake and Breast Cancer Survival: A Meta-analysis of Cohort Studies

2013 ◽  
Vol 14 (4) ◽  
pp. 2407-2412 ◽  
Author(s):  
Feng Chi ◽  
Rong Wu ◽  
Yue-Can Zeng ◽  
Rui Xing ◽  
Yang Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Food Intake ◽  
Cohort Studies ◽  
Cancer Survival ◽  
Meta Analysis ◽  
Breast Cancer Survival

scholarly journals PARP inhibitor treatment of advanced breast cancer beyond the BRCA-mutated type: a meta-analysis

2021 ◽  
Author(s):  
Feifei Yan ◽  
Qi Jiang ◽  
Mengye He ◽  
Peng Shen
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Sequential Analysis ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Parp Inhibitor ◽  
Objective Response ◽  
Parp Inhibitors ◽  
Advanced Breast ◽  
Trial Sequential Analysis

Background: We conducted this meta-analysis to compare the efficacy and safety of PARP inhibitors with or without chemotherapy versus chemotherapy alone for advanced breast cancer. Methods: A meta-analysis and trial sequential analysis were performed using RevMan 5.2 analysis software. Results: Six eligible randomized clinical trials involving 2080 patients were included. Regimens containing PARP inhibitors were significantly associated with higher objective response rate, longer progression-free survival and overall survival. The PARP inhibitor regimen group had a significantly higher rate of grade ≥3 thrombocytopenia than the chemotherapy-only group. Conclusion: Regimens containing PARP inhibitors are effective and safe for BRCA-mutated advanced breast cancer patients. The efficacy appears to be only marginal in patients with BRCA status unselected.

scholarly journals Statin use and breast cancer survival and risk: a systematic review and meta-analysis

Oncotarget ◽  
2015 ◽  
Vol 6 (40) ◽  
pp. 42988-43004 ◽  
Author(s):  
Qi-Jun Wu ◽  
Chao Tu ◽  
Yuan-Yuan Li ◽  
Jingjing Zhu ◽  
Ke-Qing Qian ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Cancer Survival ◽  
Meta Analysis ◽  
Breast Cancer Survival ◽  
Statin Use

Variations in Breast Cancer Survival Rates: A Systematic Review and Meta-Analysis of Data from the Entire Continent of Africa

2019 ◽  
Author(s):  
Paddy Ssentongo ◽  
Joseph A. Lewcun ◽  
Xavier Candela ◽  
Anna E. Ssentongo ◽  
Eustina G. Kwon ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Cancer Survival ◽  
Meta Analysis ◽  
Survival Rates ◽  
Breast Cancer Survival
Sign in / Sign up

Export Citation Format

Share Document